Clinical Trials · NCT01336023
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 1,663
- Start date
- May 2011
- Locations
- 302 sites, 20 countries
- Primary endpoint
- Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26.